A string of regulatory and operational missteps pushed several companies onto Wall Street’s downgrade list this week, even as growth-oriented names earned fresh bullish endorsements.
Bernstein analyst Jeffrey Walch slashed his rating on Summit Therapeutics (NASDAQ: SMMT) to Underperform from Market Perform, cutting his price target nearly 30% to $8.30 from $11.90.
Walch identified at least three specific failures in how Summit managed its HARMONi interaction with the U.S. Food and Drug Administration, raising fundamental questions about the company’s drug development competence.
The firm’s concerns center on an overreliance on trial results originating from China, premature data analysis conducted on four separate occasions, and an inadequate explanation of regional approval risks to investors.
Bernstein’s Cristian Rios delivered a second blow to consumer staples, downgrading PepsiCo (NASDAQ: PEP) to Underperform from Market Perform with a trimmed price target of $128, down from $131.
Rios projects that persistent weakness across North America will cause the beverage and snack giant to fall short of earnings expectations over the coming 12 months.
William Blair analyst Neal Dingmann pulled back on USA Rare Earth (NASDAQ: USAR), cutting the stock to Market Perform from Outperform and removing his prior price target, citing feedstock shortages that are compounding an already difficult near-term picture.
Those shortages are cascading through the supply chain, weighing on Less Common Metals operations and disrupting output at the Stillwater magnet plant, with Blair indicating a preference for processors with longer operational track records.
On the other side of the ledger, B. Riley lifted AST SpaceMobile (NASDAQ: ASTS) to Buy from Neutral with a $48 price target, arguing that anxiety over capital commitments, constellation deployment timelines, and the Firefly Aerospace rocket development partnership has been more than reflected in the stock’s current valuation.
BMO Capital upgraded Bloom Energy (NYSE: BE) to Outperform from Market Perform, though it nudged the price target lower to $230 from $260, citing large-scale project execution from customers including Nebius as the evidence it had been waiting for before turning constructive.
UBS delivered the most aggressive bullish call of the week, raising MongoDB (NASDAQ: MDB) to Buy from Neutral and lifting its price target to $450 from $375, projecting that the database platform could capture between 20% and 40% of new artificial intelligence workloads.
UBS believes that level of AI-driven adoption could push MongoDB’s annual revenue growth above the 20% threshold, a rate that would represent a meaningful re-acceleration for the business.
Bank of America maintained its Buy rating on MongoDB but reduced its own target to $450 from $540, with investors set to receive a clearer picture of the company’s trajectory when fiscal third-quarter results land on December 1.
The week’s analyst activity underscores a widening divide between companies demonstrating concrete execution progress in AI and energy infrastructure and those struggling with regulatory credibility or demand headwinds in core markets.